By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics reported after the close of the market Tuesday that its second-quarter 2012 revenues increased 22 percent year over year with molecular diagnostic revenues up 17 percent.

The Salt Lake City-based firm had total revenues of $122.8 million for the three-month period ended Dec. 31, 2011, compared to $100.4 million for the second quarter of 2011. It beat Wall Street's consensus estimate for revenues of $115.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.